Daniel Rosebrock

TL;DR: The flagship paper of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium describes the generation of the integrative analyses of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types, the structures for international data sharing and standardized analyses, and the main scientific findings from across the consortium studies.

TL;DR: A comprehensive genetic analysis of 304 primary DLBCLs identified low-frequency alterations, captured recurrent mutations, somatic copy number alterations, and structural variants, and defined coordinate signatures in patients with available outcome data to provide a roadmap for an actionableDLBCL classification.

TL;DR: It is demonstrated that B2M loss is a mechanism of primary and acquired resistance to therapies targeting CTLA4 or PD-1 in melanoma patients, and is associated with poorer overall survival.

TL;DR: Whole-genome sequencing data for 2,778 cancer samples from 2,658 unique donors is used to reconstruct the evolutionary history of cancer, revealing that driver mutations can precede diagnosis by several years to decades.

TL;DR: In this paper, a software called ichorCNA was proposed to quantitatively measure tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations.